title: Eyelid metastasis from breast cancer showing marked response to chemotherapy.
abstract: A patient with recurrent breast cancer, who was diagnosed with eyelid metastasis as a part of systemic metastases and in whom systemic chemotherapy was markedly effective, is reported. A 50-year-old woman underwent a radical mastectomy for stage II breast cancer in October, 1988. Histologically, the tumor was invasive lobular carcinoma. In October, 1993, the patient consulted our hospital complaining primarily of swelling of the left eyelid and restriction of movement in the left eye. Metastasis from breast cancer was diagnosed on eyelid biopsy. On further examination, metastases were detected in the liver, bone, orbit, peritoneum and pleura. Systemic combined chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil was administered intravenously at intervals of three weeks. Complete responses were obtained in the eyelid and peritoneal metastases after three courses, and in the liver metastasis after five courses. Partial responses were also observed in the bone and pleural metastases. The incidence of eyelid metastasis from breast cancer is very low, one case only having been previously reported in Japan and 34 cases abroad. Most of these cases were treated locally by surgical resection or radiotherapy, but the mean survival period was only 14 months, ranging from two months to four years. Eyelid metastasis from breast cancer should be regarded as a manifestation of systemic spread of the tumor and, in principle, treated by systemic therapy.
authors.affiliation: Department of Medical Oncology, National Cancer Center Hospital, Tokyo.
authors.forename: G J
authors.initials: GJ
authors.lastname: Zhang
authors.forename: I
authors.initials: I
authors.lastname: Adachi
authors.forename: D F
authors.initials: DF
authors.lastname: Yin
authors.forename: M
authors.initials: M
authors.lastname: Narabayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Tokue
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Kaneko
authors.forename: H
authors.initials: H
authors.lastname: Tsuda
authors.forename: K
authors.initials: K
authors.lastname: Abe
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000556:secondary*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005142:Eyelid Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000556:secondary; D015409:Mastectomy, Radical; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000556:secondary; D010534:Peritoneal Neoplasms / Q000556:secondary
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil